Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Acute myeloid leukemia Stories

2013-10-10 08:29:30

Tumor Response Observed in Patient with Refractory Small Cell Lung Cancer SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular...

2013-10-07 09:31:00

An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs that may someday benefit people with certain types of leukemia or blood cancer. Reuben Kapur, Ph.D., the Frieda and Albrecht Kipp Professor of Pediatrics at the IU School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, and colleagues discovered in pre-clinical and pharmacological models that cancer cells with a mutation in the KIT receptor...

2013-10-01 08:30:40

BERGEN, Norway, October 1, 2013 /PRNewswire/ -- Key Points - Presence of Axl receptor is an independent prognostic marker in patients with Acute Myeloid Leukemia (AML) - The Axl receptor is a novel therapeutic target in AML, an aggressive cancer that is poorly served by currently available treatments - BGB324, a first-in-class, highly selective Axl inhibitor, is currently in Phase 1 clinical testing...

2013-09-30 14:04:37

Weizmann Institute researchers discover that a “standoff” between a mutated gene and its normal counterpart keeps certain cancer cells alive What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an internal “balance of terror” to keep going. When one version of a certain gene is mutated, it becomes a cancer-promoting...

2013-09-25 04:22:15

SAN DIEGO, Sept. 25, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of U.S. Patent 8,501,924, "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof." The patent pertains to nucleic acid sequences encoding NPM mutants and methods of detecting them for diagnosing acute myeloid leukemia (AML) and monitoring residual AML disease. This is the second issued U.S. patent directed to NPM...

2013-09-19 08:28:11

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its...

2013-09-17 08:32:44

Beat AML initiative deploys advanced genetic sequencing and computing technologies to identify mutations driving the disease and develop precision therapies to stop it WHITE PLAINS, N.Y. and PORTLAND, Ore., Sept. 17, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and the Knight Cancer Institute at Oregon Health & Science University (OHSU) today announced a pioneering collaboration that brings together scientists from multiple disciplines to better understand a...

2013-09-17 08:32:39

Live Webcast from New York on Friday, September 27 SAN DIEGO, Sept. 17, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at BioCentury's NewsMakers in the Biotech Industry conference on Friday, September 27, 2013 at 2:00 p.m. Eastern time from the Millennium Broadway Hotel in New York. A live...

2013-09-17 08:30:43

RIDGEFIELD, Conn., Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy. "This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the...

2013-09-16 16:25:13

St. Jude Children's Research Hospital investigators prove that an immune marker predicts transplant success and improves selection of bone marrow donors MEMPHIS, Tenn., Sept. 16, 2013 /PRNewswire/ -- The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the...